In Caucasians throughout the world, malignant melanoma is the neoplasm with the largest increase in incidence over the past years. After initial spreading via the lymphatic system, once disseminated hematogenously, the tumor is rarely curable and patients have a mean survival of less than 6 months (/) . The criteria used most to evaluate the prognosis of patients with malignant melanoma are the histopathologic features of the tumor and the clinical presentation. However, no currently available laboratory tests provide additional prognostic information.
The ability of melanoma cells to metastasize rapidly and widely may be determined by the same traits that facilitate the migration of melanocyte precursors from the neural crest through tissues before reaching epithelial surfaces during fetal development. Melanoma cells can grow in the absence of any exogenous growth supplement and can express a variety of cell-surface adhesion molecules; both are characteristics that may contribute to their high malignant potential (2,3).
Although regional lymph node involvement indicates the likelihood of systemic involvement, dissemination probably occurs via the vascular system. Smith et al. (4) developed a highly sensitive assay for detection of circulating melanoma cells in peripheral blood. In this assay, successful reverse transcription and polymerase chain reaction (RT-PCR) amplification of sequences in the messenger RNA (mRNA) encoding the glycoprotein tyrosinase, a specific enzyme in the melanin biosynthesis (5), indicates the presence of tumor cells in blood, since normal melanocytes are not expected to circulate. This approach may prove to be useful in learning more about the mechanisms of metastatic spread, and it may establish a new prognostic marker to select treatment options and evaluate the anticipated duration of survival in malignant melanoma. To assess the prognostic value of tyrosinase mRNA detection by this method, we examined blood samples from 64 patients with different tumor burdens and various sites and stages of disease.
Patients and Methods
Samples of peripheral blood were collected from 64 patients with histologically confirmed malignant melanoma who attended the outpatient clinic of the Medizinische Hochschule Hannover, Federal Republic of Germany, between August 1992 and June 1994. Sixteen disease-free patients with a history of primary malignant melanoma were seen and sampled at routine follow-up visits, and 48 patients were tested in the presence of disseminated malignant melanoma [stages nib and IV TNM/Intemational Union Against Cancer (6)]. For all patients, tumor status was re-evaluated prior to sample collection according to World Health Organization criteria (7) . Patient characteristics are given in Table  1 . Samples of peripheral blood were also obtained from five healthy donors and four patients with other cancers (minimal essential information appears in a footnote to Table 1 ). The study was approved by the Institutional Review Board at the Medizinische Hochschule Hannover and written, informed consent was obtained from all patients and control subjects.
RT-PCR Assay for Detection of Tyrosinase mRNA
For analysis of tyrosinase mRNA, RT-PCR was performed as previously described by Smith et al. (4) . Total cellular RNA was extracted from heparinized peripheral blood with the use of the RNAzol A method (Cinna Biotexc, Houston, TX) (8) . Blood mRNA integrity was checked by RT with random hexamer primers and consecutive PCR with primers for human (J-actin (5' ATG GAT GAT GAT ATC GCC GCG and 3' TCT CCA TGT CGT CCC AGT TG), producing a fragment of 248 base pair (bp) (9) . For PCR analysis of tyrosinase transcripts, two sets of primers were devised from the published sequences as follows (4): HTYR1 (5' TTG GCA GAT TGT CTG TAG CC) and HTYR2 (3' AGG CAT TGT GCA TGC TGC TT), which yield a PCR product of 284 bp, and HTYR3 (5' GTC TTT ATG CAA TGG AAC GC) and HTYR4 (3' GCT ATC CCA GTA AGT GGA CT), which yield a PCR product of 207 bp. For sensitivity testing, we performed a 10-fold serial dilution of the established human melanoma-derived cell lines SK-mel 1 (10) and SK-mel 3 (11) (American Type Culture Collection, Rockville, MD) in heparinized blood from a healthy donor to obtain decreasing concentrations of melanoma cells (10 6 -10 melanoma cells/mL). As positive controls, we used RNA from about 10 cells from the melanoma cell lines SK-mel 30 and RPMI-7951 (American Type Culture Collection) (12) . For RT, 10 uL RNA was heated at 90 'C for 5 minutes, cooled rapidly on ice, and diluted to 20 |iL with a mixture containing final concentrations of 1 x PCR buffer, 1 mmol/L of each deoxynucleoside triphosphate (dNTP; deoxyadenosine triphosphate, deoxycytidine triphosphate, deoxyguanosine triphosphate, and deoxythymidine triphosphate), 8 mmol/L MgCl 2 , 25 pmol HTYR2, 20 U "RNAguard" (Pharmacia, Freiburg, Federal Republic of Germany), and 4 U Moloney murine leukemia virus RT (Pharmacia). After incubation at 37 'C for 1 hour, 10 |iL of the sample was suspended in 50 pX PCR buffer containing final concentrations of 200 nmol/L of each dNTP, 1.6 mmol/L MgCl 2 , 150 pmol HTYR1 and HTYR2, and 1 U Taq DNA polymerase (Promega Corp., Madison, WI). Each sample was overlaid with oil. PCR was carried out with a Thermocycler TCV 45 (Landgraf, Langenhagen, Federal Republic of Germany). After initial heating at 94 'C for 5 minutes, 30 cycles of PCR were then carried out (94 'C for 75 seconds, 60 'C for 75 seconds, and 72 'C for 75 seconds). For reamphfication with the nested primers HTYR3 and HTYR4, 5 pi of a 1 in 100 dilution was amplified in a 25-uL reaction volume for an additional 30 cycles. For analysis, 8.5 HL of reaction product was run on a 3% agarose gel (NuSieve, Rockland, ME), followed by ethidium bromide staining. The specificity of the amplified products was established by restriction enzyme digestion. To avoid contamination, RNA extraction and RT-PCR were done in two different areas. Precautions were taken to prevent transfer of material between the two areas. All components except RNA and DNA were prepared in a laminar air flow cabinet, and positive displacement pipettes were used.
Data Analysis and Statistical Methods
Survival curves were constructed using KaplanMeier estimates (13) . Differences in survival distribution were tested with the Mantel-Cox (logrank) analysis (14) ; other two-sided tests applied were Tarone-Ware (15) and generalized Wilcoxon (16) .
Results

Sensitivity and Specificity of the RT-PCR Method
Using the RT-PCR technique as described above, tyrosinase transcripts could be detected in all samples from cultured human melanoma cell lines (SKmel 1, SK-mel 3, SK-mel 30, and RPMI-7951). The specificity of the amplified PCR products was established by the size of the fragments, deduced from their electrophoretic mobility (207 bp after reamplification with nested primers), and restriction enzyme digestion. To determine the sensitivity of the method, we performed 10-fold serial dilution experiments. Dilution series with decreasing numbers of cells of SK-mel 1 and SK-mel 3, mixed in blood from a healthy donor, showed a sensitivity of up to one cell per 10 6 peripheral blood mononuclear cells (Fig. 1, A and data not shown) .
Healthy Donors and Patients With Other Cancers
Blood samples from five healthy donors all tested negative by RT-PCR for tyrosinase transcripts (tyrosinase negative). Also, we could not amplify tyrosinase mRNA in blood samples from two patients with renal cell carcinoma, from one patient with parotideal gland carcinoma, and from one patient with colorectal cancer (data not shown).
Tyrosinase mRNA Positivity and Stage of Disease
We tested peripheral blood samples from 64 patients with malignant melanoma in different stages of disease for the presence of tyrosinase transcripts. Patient characteristics are shown in Table 1 . All patients with localized primary melanoma (n = 16) tested negative for tyrosinase mRNA and continued to be disease free at 8+ to 16+ months (median, 12+ months) from time of sampling.
Among patients with metastatic disease who were tested (n = 48), all those with no evidence of disease progression (total, n = 27 [cutaneous, n = 2; lymphatic, n = 9 --9 ---9
*Unless otherwise specified, values = number of subjects. mRNA = messenger RNA. tTwo females and three males; median age, 27 y (range, 26-35 y). JUpon sampling. §Remissions, disease stabilization, and progression were assessed over an 8-week interval prior to tyrosinase mRNA sampling; patients received chemotherapy/immunotherapy, including dacarbazine, carmustine, cisplatin, interleukin 2, and interferon alfa.
NPatients with visceral metastases may have also developed lymphatic and/or cutaneous diseases (see Table 2 ).
12; visceral, n = 13)) were found to be tyrosinase mRNA negative. In contrast, among 21 patients with progressive metastatic disease (lymphatic, n = 2; and viscera], n = 19), tyrosinase mRNA was detected by RT-PCR in nine patients (tyrosinase positive; Fig. 1, B) , all of whom presented with acute visceral progression. Patient characteristics are shown in Table 2 . Four tyrosinase-positive patients were tested sequentially and found to be tyrosinase negative at times without evidence of tumor progression; one patient became negative after achieving stable disease and three patients became positive after tumor progression.
Tyrosinase mRNA Positivity and Survival
Kaplan-Meier survival is shown in Fig. 2 . In tyrosinase-positive patients (n = 9; all with visceral metastases), the probability of survival from time of tyrosinase mRNA sampling was significantly reduced (median, 4 months) when compared with that of all tyrosinase-negative patients (n = 55; median not reached after 16 months: significance levels were calculated at /><.00001 [Mantel-Cox, Tarone-Ware, and generalized Wilcoxon]). Furthermore, a significant reduction in the probability of survival was found in comparison with tyrosinasenegative patients with metastatic disease (n = 39; median, 12 months; P5.0006 [Mantel-Cox] 
Discussion
The most widely accepted criteria for the evaluation of prognosis of malignant melanoma are histopathologic and clinical presentation. It has recently been suggested that the RT-PCR-based detection of tyrosinase mRNA in peripheral blood might be useful toward the early detection of circulating melanoma cells, since tyrosinase is thought to be a melanocytespecific marker {4, [17] [18] [19] [20] [21] . To evaluate the clinical relevance of this potential marker, we prospectively examined blood samples from 64 patients with melanoma in different stages of disease for the presence of tyrosinase transcripts. All patients with localized primary melanoma tested negative for tyrosinase mRNA and continued to be disease free at 8+ to 16+ months from time of sampling. Among patients with metastatic disease who were tested, all those achieving complete remission or stable disease exhibited tyrosinase mRNA negativity. In contrast, of the 21 patients with progressive metastases, nine tested tyrosinase mRNA positive, all of whom had visceral disease. In tyrosinase-positive patients, probability of survival from time of tyrosinase mRNA sampling was significantly reduced (median, 4 months) when compared with all tyrosinase-negative patients, tyrosinase-negative patients with metastatic disease, and tyrosinase-negative patients with progressive visceral metastases.
While others (19) have reported molecular detection of circulating tumor cells in patients with malignant melanoma without clinical evidence of disease, our RT-PCR tests yielded a significant proportion of tyrosinase mRNA-negative patients only in the presence of distant metastasis. In this study, sensitivity and specificity of RT-PCR have been established. Notably, the finding of tyrosinase negativity in metastatic disease is in accordance with RT-PCR testing of circulating tumor cells in patients with prostate cancer for the presence of prostatespecific antigen mRNA, whereby a significant proportion of patients with metastatic disease were found to be negative for this mRNA (22) . In the present experiments, consistent detection of intact (3-actin mRNA did not support the hypothesis of spontaneous degradation of tyrosinase mRNA. Rather, malignant melanoma cells may be shed intermittently in the circulation, leading to sampling errors; our findings may also be explained by a down-regulation (i.e., decrease) of tyrosinase mRNA transcription or an in- crease in the turnover of the mRNA itself. Both of these possibilities need to be explored.
The results of this study demonstrate for the first time that the detection of tyrosinase mRNA in cells present in peripheral blood could serve as a marker of rapid tumor progression and poor clinical outcome. Before such assays involving the molecular detection of circulating tumor cells can be introduced in the clinic, the issue of quality assurance programs must be addressed, both for the standardization of methods between different laboratories and for a better definition of the sensitivity and the specificity of the diagnostic and prognostic methods employed in patient management.
